The FDA has granted a breakthrough therapy designation to the tumor-infiltrating lymphocyte therapy LN-145 for the treatment of patients with recurrent, metastatic, or persistent cervical cancer with disease progression on or after chemotherapy.
Ernest S. Han, MD, PhD, FACOG, discusses the role of HIPEC in advanced ovarian cancer at the time of interval debulking, as well as anticipated research examining its use at time of primary debulking.
Ana Oaknin, MD, provides insight into the implications of the GARNET trial and the promise of dostarlimab in endometrial cancer.
Improved outcomes such as longer survival have increased interest among patients in pursuing fertility preservation options, and advances in techniques have made it possible for more patients to have children after treatment.
The antibody-drug conjugate mirvetuximab soravtansine demonstrated a favorable benefit-risk profile in a prespecified subset of patients with folate receptor alpha–positive ovarian cancer, following a comprehensive analysis of the phase III FORWARD I trial.
The European Committee for Medicinal Products for Human Use has recommended approval of olaparib as a frontline maintenance treatment for patients with BRCA-mutant advanced high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response following first-line platinum-based chemotherapy.
Investigational data are associated with folate receptor alpha-targeting agents, with an emphasis on the recent development and therapeutic potential of antibody-drug conjugates for the treatment of patients with ovarian cancer.
The combination of the PARP inhibitor olaparib (Lynparza) and the pan-HER TKI neratinib (Nerlynx) proved to be highly synergistic and demonstrated significant activity in preclinical models of HER2-positive uterine serous carcinoma.
Although there are several maintenance strategies to consider for patients with advanced ovarian cancer, the decision of which approach to pursue largely depends on the molecular makeup of an individual patient’s tumor.
Chrisann Kyi, MD, discusses the utility of PARP inhibitors in the primary treatment and maintenance settings for patients with recurrent ovarian cancer and the next steps that lie ahead.